메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Cloopen Announces Changes to Board of Directors and Committee Membership

BEIJING, Feb. 5, 2026 -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company") today announced that its Board of Directors (the "Board") has approved resolutions regarding changes to the composition of the Board and the Compensation Committee, effective February 5, 2026. Board Composition and Re-appointments The Company announced that Mr. Qingsheng Zheng and Mr. Ye Yuan have tendered their resignations as directors of the Board for personal reasons. Both Mr. Zheng and Mr. Yuan have confirmed that they have no disagreement with the Company
- 황정호 기자
- 2026-02-05 20:00
Agility：世界の物流業界幹部、2026年を不確実な年であると予測

業界はAI、コスト管理、サプライチェーン・リエンジニアリングに注目アブダビ（アラブ首長国連邦）, 2026年2月5日 -- 2026年Agility新興市場物流指数によると、物流の経営幹部は貿易、地政学、世界経済が不安定な1年に備え、AIに目を向け、コストを精査し、サプライチェーンを再構築することで不確実性に対処しています。業界の専門家503人を対象とした調査において、86%が、2026年に不確実性が高まると予想している、または貿易や政治、経済の乱高下を「ニューノーマル」と見ていると回答しています。 Agilityの調査によると、ほぼ全世界の物流業界はAIを導入しているとのことです。回答者の98％が、自社のサプライチェーンや業務の一部を管理するために人工知能を利用していると答えています。また、この調査は、グローバルな生産と調達シフトが、最初にCOVID、次いで米中摩擦、そして昨年の関税引き上げの波によって拍車がかかり、企業がサプライチェーンを再構築・微調整する中で、今日も続いていることを示唆しています。 AgilityのTarek Sultan会長は、「企業や政府のリーダーは、快適な場所や休息する時間がないことを理解しています。しかし彼らは不確実性の
- 황정호 기자
- 2026-02-05 19:53
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan. Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode t
- 김갑성 기자
- 2026-02-05 19:44
Only Small Group of Banks Are Turning AI into Revenue, New Research Finds

SINGAPORE, Feb. 5, 2026 -- Dyna.Ai, a global provider of AI solutions, today released a new executive insights report, developed in collaboration with GXS Partners and Smartkarma, examining why most banks struggle to translate AI investment into revenue, and how a small group is breaking through. The report highlights how financial institutions across Southeast Asia, Latin America, and the Middle East are unlocking revenue through a small number of AI capabilities, while emphasizing the operational conditions required to scale these in production. The research finds that banks successf
- 황정호 기자
- 2026-02-05 19:43
Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

SHANGHAI, Feb. 5, 2026 -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion. Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company's development in the D round. Before the company's IPO, Qiming Ventur
- 김갑성 기자
- 2026-02-05 19:39
Multifonds and Ultumus Join Forces to Accelerate ETF Expansion in Europe, Asia and North America

[ 메디채널 황정호 기자 ] Strategic Combination Provides Asset Managers, Fund Administrators and Transfer Agents with an Integrated solution to support Exchange-Traded Funds LUXEMBOURG, Feb. 5, 2026 -- Multifonds, a leading global provider of fund administration software and SaaS solutions and Ultumus, a SIX Group company specialising in ETF infrastructure technology, today announced a strategic partnership designed to enable fund providers to rapidly expand into the fast-growing ETF market. The collaboration gives Multifonds' clients direct access to Ultumus' specialised ETF te
- 황정호 기자
- 2026-02-05 18:09
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

[ 메디채널 김갑성 기자 ] Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical
- 김갑성 기자
- 2026-02-05 17:09
Dingdong Announces Entry into Definitive Agreement to Sell its China Business to Meituan

SHANGHAI, Feb. 5, 2026 -- Dingdong (Cayman) Limited ("Dingdong" or the "Company") (NYSE: DDL), a leading fresh grocery e-commerce company in China, today announced that it has entered into a definitive Share Purchase Agreement (the "Share Purchase Agreement") with Two Hearts Investments Limited ("Buyer"), a wholly-owned subsidiary of Meituan (HKEX: 3690). Pursuant to the Share Purchase Agreement, Dingdong has agreed to sell to the Buyer all issued and outstanding shares of Dingdong Fresh Holding Limited, Dingdong's wholly-owned subsidiary incorpo
- 황정호 기자
- 2026-02-05 17:08
ATFX Global Head of Marketing Weems Chan Receives Prestigious "Hong Kong's Woman Leaders" Award

HONG KONG, Feb. 5, 2026 -- ATFX is proud to announce that its Global Head of Marketing, Ms. Weems Chan, has been honoured with the esteemed "Hong Kong's Woman Leaders" Award by the World Women Leadership Congress (WWLC). The award recognises leaders who make a real impact by guiding diverse teams and managing complex projects across different markets. A Collective Achievement and Leadership Philosophy The recognition reflects Ms. Chan's leadership journey and her contributions to ATFX and the wider business community. Reflecting on the honour, Ms. Chan described the aw
- 황정호 기자
- 2026-02-05 17:00
Signing of strategic technology supply and offtake agreement with Carester, US$20 million equity investment from the Industrial Development Corporation, and commencement of DFS for the Zandkopsdrift magnet rare earths and battery grade manganese project in South Africa

LUXEMBOURG, Feb. 5, 2026 -- Frontier Rare Earths Limited ("Frontier" or the "Company"), which is developing the Zandkopsdrift magnet rare earths and battery grade manganese project in South Africa, is pleased to announce the signing of a Technology Supply Agreement with Carester SAS ("Carester"), one of the leading western rare earths separation specialists, and an investment of US$20m from South Africa's Industrial Development Corporation to finance a Definitive Feasibility Study ("DFS"), with first production targeted for 2030.
- 황정호 기자
- 2026-02-05 17:00

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 20분